{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T07:00:34Z","timestamp":1760425234163,"version":"3.37.3"},"reference-count":35,"publisher":"Informa UK Limited","issue":"2","license":[{"start":{"date-parts":[[2014,3,20]],"date-time":"2014-03-20T00:00:00Z","timestamp":1395273600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020139","name":"ArQule","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100020139","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Hepatic Oncol."],"published-print":{"date-parts":[[2014,4]]},"DOI":"10.2217\/hep.14.3","type":"journal-article","created":{"date-parts":[[2014,2,5]],"date-time":"2014-02-05T15:57:24Z","timestamp":1391615844000},"page":"181-188","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":15,"title":["Tivantinib in MET-high hepatocellular carcinoma patients and the ongoing Phase III clinical trial"],"prefix":"10.1080","volume":"1","author":[{"given":"Lorenza","family":"Rimassa","sequence":"first","affiliation":[{"name":"Medical Oncology & Hematology Unit,Cancer Center,Humanitas Clinical & Research Center,\rVia Manzoni 56,\r20089\rRozzano,\rMilan,\rItaly."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camillo","family":"Porta","sequence":"additional","affiliation":[{"name":"Fondazione IRCCS Policlinico San Matteo,\rP.le Golgi 19,\r27100Pavia,\rItaly"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivan","family":"Borbath","sequence":"additional","affiliation":[{"name":"Cliniques Universitaires Saint-Luc,\rAvenue Hippocrate 10,\rBrussels,\r1200,\rBelgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno","family":"Daniele","sequence":"additional","affiliation":[{"name":"G. Rummo Hospital,\rVia Dell\u2018Angelo, 1,\r82100,\rBenevento,\rItaly"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard S","family":"Finn","sequence":"additional","affiliation":[{"name":"Department of Medicine,Hematology\/Oncology,Geffen School of Medicine at University of California,Los Angeles,\r10833 Le Conte Avenue,\rCA,\rUSA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Luc","family":"Raoul","sequence":"additional","affiliation":[{"name":"Paoli-Calmettes Institute,232 Boulevard de Sainte Marguerite,\rBP 156, Marseille Cedex 09,\r13273,\rFrance"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lawrence H","family":"Schwartz","sequence":"additional","affiliation":[{"name":"Columbia University,\r180 Fort Washington Avenue,\rNY10032,\rUSA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aiwu Ruth","family":"He","sequence":"additional","affiliation":[{"name":"Georgetown University Hospital,Lombardi Comprehensive Cancer Center;\r3800 Reservoir Road NW, Washington, DC,\r20007,\rUSA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joerg","family":"Trojan","sequence":"additional","affiliation":[{"name":"Klinikum der Johann Wolfgang Goethe-Universit\u00e4t,\rTheodor-Stern-Kai 7 Frankfurt am Main,\r60590,\rGermany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus","family":"Peck-Radosavljevic","sequence":"additional","affiliation":[{"name":"Medizinische Universitaet Wien,Abteilung fuer Gastroenterologie und Hepatologie,\rFloor 6 P, Waehringer G\u00fcrtel 18\u201320,\rVienna,\r1090,\rAustria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Abbadessa","sequence":"additional","affiliation":[{"name":"ArQule, Inc.,\r19 Presidential Way,\rWoburn,\rMA 01801,\rUSA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Terri","family":"Goldberg","sequence":"additional","affiliation":[{"name":"Daiichi-Sankyo, Inc,\rEdison,\rNJ 08837,\rUSA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Armando","family":"Santoro","sequence":"additional","affiliation":[{"name":"Medical Oncology & Hematology Unit, Cancer Center,Humanitas Clinical & Research Center,\rVia Manzoni 56,\r20089Rozzano,\rMilan,\rItaly"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jordi","family":"Bruix","sequence":"additional","affiliation":[{"name":"Barcelona Clinic Liver Cancer Group,Liver Unit,Hospital Clinic,University of Barcelona,IDIBAPS,CIBERehd,\rVillarroel 170,\r08036Barcelona,\rSpain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2014,3,20]]},"reference":[{"doi-asserted-by":"publisher","key":"e_1_3_4_3_1_1","DOI":"10.3322\/caac.20107"},{"doi-asserted-by":"publisher","key":"e_1_3_4_3_2_1","DOI":"10.1056\/NEJMoa0708857"},{"doi-asserted-by":"publisher","key":"e_1_3_4_3_3_1","DOI":"10.1016\/S1470-2045(08)70285-7"},{"doi-asserted-by":"publisher","key":"e_1_3_4_3_4_1","DOI":"10.1158\/1078-0432.CCR-09-2084"},{"doi-asserted-by":"publisher","key":"e_1_3_4_3_5_1","DOI":"10.1002\/hep.26586"},{"doi-asserted-by":"publisher","key":"e_1_3_4_3_6_1","DOI":"10.1200\/JCO.2012.47.3009"},{"key":"e_1_3_4_3_7_1","volume-title":"Presented at: 37th European Society for Medical Oncology Congress","author":"Zhu AX","year":"2012","unstructured":"Zhu AX , RosmorducO, EvansJet al. SEARCH: a Phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with hepatocellular carcinoma (HCC). Presented at: 37th European Society for Medical Oncology Congress. Vienna, Austria, 28 September\u20131 October 2012 (Abstract 917)."},{"issue":"34","key":"e_1_3_4_3_8_1","article-title":"Phase III trial of linifanib versus sorafenib in patients with advanced hepatocellular carcinoma (HCC).","volume":"30","author":"Cainap C","year":"2012","unstructured":"Cainap C , QinS, HuangWTet al. Phase III trial of linifanib versus sorafenib in patients with advanced hepatocellular carcinoma (HCC). J. Clin. Oncol. 30(Suppl. 34), Abstract 249 (2012).","journal-title":"J. Clin. Oncol."},{"doi-asserted-by":"publisher","key":"e_1_3_4_3_9_1","DOI":"10.1200\/JCO.2012.45.8372"},{"doi-asserted-by":"publisher","key":"e_1_3_4_3_10_1","DOI":"10.1200\/JCO.2012.48.4410"},{"doi-asserted-by":"publisher","key":"e_1_3_4_3_11_1","DOI":"10.1038\/nrc3205"},{"doi-asserted-by":"publisher","key":"e_1_3_4_3_12_1","DOI":"10.1002\/hep.24450"},{"doi-asserted-by":"publisher","key":"e_1_3_4_3_13_1","DOI":"10.1016\/S1535-6108(03)00085-0"},{"doi-asserted-by":"publisher","key":"e_1_3_4_3_14_1","DOI":"10.1158\/1078-0432.CCR-12-1281"},{"doi-asserted-by":"publisher","key":"e_1_3_4_3_15_1","DOI":"10.1158\/0008-5472.CAN-10-0489"},{"doi-asserted-by":"publisher","key":"e_1_3_4_3_16_1","DOI":"10.1016\/S1470-2045(12)70490-4"},{"doi-asserted-by":"publisher","key":"e_1_3_4_3_17_1","DOI":"10.1200\/JCO.2010.34.0570"},{"key":"e_1_3_4_3_18_1","volume-title":"Presented at: Annual Meeting of the American Association for Cancer Research.","author":"Rodig S","year":"2012","unstructured":"Rodig S , SequistLV, SchillerJHet al. An exploratory biomarker analysis evaluating the effect of the c-met inhibitor tivantinib (ARQ 197) and erlotinib in NSCLC patients in a randomized, double-blinded Phase 2 study. Presented at: Annual Meeting of the American Association for Cancer Research. Chicago, IL USA, 31 March\u20134 April 2012 (Abstract 1729)."},{"doi-asserted-by":"publisher","key":"e_1_3_4_3_19_1","DOI":"10.1158\/1535-7163.MCT-09-1173"},{"key":"e_1_3_4_3_20_1","volume-title":"Presented at: 100th Annual Meeting of the American Association for Cancer Research.","author":"Chen CR","year":"2009","unstructured":"Chen CR , SzwayaJ, RojnuckarinAet al. Combination studies of tyrosine kinase inhibitors (TKIs): assessment of potential cytotoxic synergy of ARQ 197 with sorafenib or sunitinib. Presented at: 100th Annual Meeting of the American Association for Cancer Research. Chicago, IL, USA, 18\u201322 April 2009 (Abstract 820)."},{"key":"e_1_3_4_3_21_1","volume-title":"Presented at: AACR Annual Meeting.","author":"Jeay S","year":"2007","unstructured":"Jeay S , MunshiN, HillJet al. ARQ 197, a highly selective small molecule inhibitor of c-MET, with selective anti-tumor properties in a broad spectrum of human cancer cells. Presented at: AACR Annual Meeting. Los Angeles, CA, USA, 14\u201318 April 2007 (Abstract 2369)."},{"doi-asserted-by":"publisher","key":"e_1_3_4_3_22_1","DOI":"10.1158\/1078-0432.CCR-12-3459"},{"doi-asserted-by":"publisher","key":"e_1_3_4_3_23_1","DOI":"10.1158\/0008-5472.CAN-12-3256"},{"key":"e_1_3_4_3_24_1","volume-title":"Presented at: American Association for the Study of Liver Diseases Annual Meeting.","author":"Lu S","year":"2013","unstructured":"Lu S , RizzaniA, KolligsFTDe ToniENet al.. Anti-proliferative mechanisms downstream of c-MET of the kinase inhibitor tivantinib (ARQ 197). Presented at: American Association for the Study of Liver Diseases Annual Meeting. Washington DC, USA, 1\u20135 November 2013 (Abstract 1818)."},{"issue":"8","key":"e_1_3_4_3_25_1","article-title":"The novel c-MET inhibitor, ARQ 197, shows additive growth-inhibitory effect with erlotinib through enhanced degradation of c-MET protein via ubiquitin\/proteasome pathway.","volume":"70","author":"Kanome T","year":"2010","unstructured":"Kanome T , KadofukuT, YamaokaTet al. The novel c-MET inhibitor, ARQ 197, shows additive growth-inhibitory effect with erlotinib through enhanced degradation of c-MET protein via ubiquitin\/proteasome pathway. Cancer Res. 70(8), Abstract 1639 (2010).","journal-title":"Cancer Res."},{"doi-asserted-by":"publisher","key":"e_1_3_4_3_26_1","DOI":"10.1158\/1535-7163.MCT-13-0187"},{"doi-asserted-by":"publisher","key":"e_1_3_4_3_27_1","DOI":"10.1021\/cb400660a"},{"doi-asserted-by":"publisher","key":"e_1_3_4_3_28_1","DOI":"10.1200\/JCO.2010.31.0367"},{"doi-asserted-by":"publisher","key":"e_1_3_4_3_29_1","DOI":"10.1158\/1078-0432.CCR-13-1321"},{"issue":"3","key":"e_1_3_4_3_30_1","article-title":"MET inhibitor tivantinib (ARQ 197) plus erlotinib vs erlotinib plus placebo in NSCLC.","volume":"49","author":"Scagliotti GV","year":"2013","unstructured":"Scagliotti GV , NovelloS, RamlauRet al. MET inhibitor tivantinib (ARQ 197) plus erlotinib vs erlotinib plus placebo in NSCLC. Eur. J. Cancer 49(3), Abstract 3410 (2013).","journal-title":"Eur. J. Cancer"},{"doi-asserted-by":"publisher","key":"e_1_3_4_3_31_1","DOI":"10.1200\/jco.2013.31.15_suppl.3508"},{"doi-asserted-by":"publisher","key":"e_1_3_4_3_32_1","DOI":"10.1038\/bjc.2012.556"},{"doi-asserted-by":"publisher","key":"e_1_3_4_3_33_1","DOI":"10.1200\/jco.2012.30.15_suppl.4117"},{"issue":"9","key":"e_1_3_4_3_34_1","first-page":"ix224","article-title":"MET as prognostic factor and therapeutic target in pretreated hepatocellular carcinoma (HCC): final results of a randomized controlled Phase 2 trial (RCT) with tivantinib (ARQ 197).","volume":"23","author":"Daniele B","year":"2012","unstructured":"Daniele B , RimassaL, BorbathIet al. MET as prognostic factor and therapeutic target in pretreated hepatocellular carcinoma (HCC): final results of a randomized controlled Phase 2 trial (RCT) with tivantinib (ARQ 197). Ann. Oncol. 23(Suppl. 9),ix224\u2013ix257 (2012).","journal-title":"Ann. Oncol."},{"unstructured":"Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma Who Have Been Treated With One Prior Therapy (METIV-HCC)\n. www.clinicaltrials.gov\/ct2\/show\/NCT01755767?term=NCT01755767&rank=1","key":"e_1_3_4_3_35_1"}],"container-title":["Hepatic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/hep.14.3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,18]],"date-time":"2024-05-18T01:20:40Z","timestamp":1715995240000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/hep.14.3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3,20]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,4]]}},"alternative-id":["10.2217\/hep.14.3"],"URL":"https:\/\/doi.org\/10.2217\/hep.14.3","relation":{},"ISSN":["2045-0923","2045-0931"],"issn-type":[{"type":"print","value":"2045-0923"},{"type":"electronic","value":"2045-0931"}],"subject":[],"published":{"date-parts":[[2014,3,20]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ihep20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ihep20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2014-03-20","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}